Crossmark

A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients

Crossref DOI link: https://doi.org/10.1016/j.medine.2021.10.016

Published Print: 2023-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Moreno, G.

Ruiz-Botella, M.

Martín-Loeches, I.

Gómez Álvarez, J.

Jiménez Herrera, M.

Bodí, M.

Armestar, F.

Marques Parra, A.

Estella, Á.

Trefler, S.

Jorge García, R.

Murcia Paya, J.

Vidal Cortes, P.

Díaz, E.

Ferrer, R.

Albaya-Moreno, A.

Socias-Crespi, L.

Bonell Goytisolo, J.M.

Sancho Chinesta, S.

Loza, A.

Forcelledo Espina, L.

Pozo Laderas, J.C.

deAlba-Aparicio, M.

Sánchez Montori, L.

Vallverdú Perapoch, I.

Hidalgo, V.

Fraile Gutiérrez, V.

Casamitjana Ortega, A.M.

Martín Serrano, F.

Nieto, M.

Blasco Cortes, M.

Marín-Corral, J.

Solé-Violán, J.

Rodríguez, A.
License Information

Text and Data Mining valid from 2023-01-01
More Information

This article is maintained by: Elsevier

Article Title: A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients

Journal Title: Medicina Intensiva (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medine.2021.10.016

Content Type: article

Copyright: © 2021 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.